Scott Iyama is a member of the Emerging Companies Group, which advises high growth companies and venture capital firms. Mr. Iyama's practice includes the formation, financing and general corporate counseling of emerging growth private and public companies; representation of venture capital firms and investment banks in private and public offerings; and other strategic transactions.

Mr. Iyama has completed hundreds of private financings and numerous mergers, acquisitions and licensing transactions. Some of his clients have included the following.

Life Science

• AcroMetrix
• Aridis Pharmaceuticals
• BenefitPoint
• CELLective Dx
• Halcyon Molecular
• Hotspur Technologies
• ImmunePath
• Laserscope
• LS9
• Precise Light Surgical
• Qliance Medical Management
• Single Cell Technology
• Telome Health

Information Technology, Internet and Digital Media

• Apple
• Burbn (aka Instagram)
• Facebook
• Quora
• Say Media
• Vendavo
• YieldEx
• Zoosk

Prior to receiving his J.D. from Stanford Law School, Mr. Iyama performed extensive biochemical research at the University of California, San Diego, and Genentech, Inc., and was a research intern at the NASA Ames Research Center.

Mr. Iyama frequently lectures on topics related to emerging growth companies at forums such as National Cancer Institute Investor Forum, Stanford University, Stanford Law School and the San Jose BioCenter. Recent lectures have included the following:

• "Anatomy of a Venture Financing"
• "Sourcing and Negotiating Deals with BioPharma"
• "Innovation: How BioPharma is Getting it Done"
• "Venture Capital Investments by BioPharma"
• "Planning for Commercial Success in Bio/BioConvergence"

Admitted in

• California
• United States Patent and Trademark Office

Memberships

• State Bar of California
• Board of Advisors, San Jose BioCenter

Publications

• "The USPTO's Proposal of a Biological Research Tool Patent Pool Doesn't Hold Water," 57 Stan. L. Rev. 1223 (2005).